| Theme | Recent Topics of Hereditary Colorectal Disease | |
|---|---|---|
| Title | Clinical Management of HNPCC | |
| Publish Date | 2008/08 | |
| Author | Masashi Ueno | Department of Gastrointestinal Surgery, Cancer Institute Hospital |
| Author | Yoshiya Fujimoto | Department of Gastrointestinal Surgery, Cancer Institute Hospital |
| Author | Hiroya Kuroyanagi | Department of Gastrointestinal Surgery, Cancer Institute Hospital |
| Author | Masatoshi Ohya | Department of Gastrointestinal Surgery, Cancer Institute Hospital |
| Author | Masahiro Igarashi | Department of Internal Medicine, Cancer Institute Hospital |
| Author | Naoyuki Uragami | Department of Internal Medicine, Cancer Institute Hospital |
| Author | Masami Arai | Clinical Genetic Oncology, Cancer Institute Hospital |
| [ Summary ] | Surveillance examinations for colorectal cancer and other organs of cancer related to HNPCC should be recommended according to HNPCC guidelines, which are based on available evidence concerning screening outcome. Some studies have also reported on cancer risk in relation to type of mutation. MSH2 carriers are at a greater risk of extra-colonic cancer and MSH6 related endometrial cancer. Gastric cancer risks are higher in Asian families with HNPCC. No formal research has been conducted showing that prophylactic subtotal colectomy is superior to segmental resection plus colonoscopic surveillance. Therefore, the option of extensive resection should be recommended in relation to the patient's age, history and planned treatment mode. The effects of chemotherapy on patients with HNPCC tumors have only been reported in a few experimental studies, so there is no definitive recommendation for chemotherapy. |
|